Date: 31 October 2023 (Tuesday)

Time: 09:00 - 12:30 

Venue: The BASE, HKUSTEntrepreneurship Center (1/F, near lift 29&30)

Host: HKUST Collaborative Innovation Centre (HCIC)

Co-organizer: Beijing Institute of Collaborative Innovation (BICI) 

 

 

 

Beijing Institute of Collaborative Innovation (BICI)  is a longstanding partner of HKUST. Through the HKUST Collaborative Innovation Center (HCIC), a joint initiative of BICI and HKUST, we provide various resources for project teams at all stages, from cutting-edge research to technology transfer and startup companies. These resources include funding, industry connections, and support for building teams, among others, to facilitate the process of technology commercialization. 

 

Highlights of this event will include:

  • Real world commercialization case studies and analysis
  • Sharing sessions with deep-tech investor and startup CEO
  • Funding schemes supported by BICI: Engineering Project, MOST Disruptive Project, etc
  • Insights into how BICI collaborates with professors to apply for RAISe+
  • One-on-one project discussions (reservation required)

 

 

ALL FACULTY AND STUDENTS interested in bringing their technologies to market are welcome to join us!

 

Rundown

 

Time Session Speaker
9:00-9:15 Registration/ Coffee& Tea -
9:15-9:30

Welcome remarks

Group Photo

Prof. Richard Hau Yue SO
Director of HCIC; Associate Dean of Engineering 
(Research & Graduate Studies) 

9:30-10:20

Bridging Research to Impact: BICI Funding Models and Case Studies

Dr. ZHOU Xinjian
Co-President of Beijing Institute of Collaborative Innovation (BICI)  
President of BICI USA 

10:20-11:00

Disruptive Technology Project Funding Scheme 

Dr. WANG Duoxiang
President of BICI
11:00-11:15 Coffee break and networking -
11:15-11:40

Research, Technology and Entrepreneurship

Dr. WANG Junqi
CEO of ChromX Health Ltd.
11:40-12:05

Early-stage Technology Investment: What Do Investors Really Value?

Ms. LI Li
Investment Director, BASF Venture Capital
12:05-12:15 Open Q&A session  -

 

 

Speakers

 

Dr. WANG Duoxiang

President of Beijing Institute of Collaborative Innovation (BICI)

 

President of Beijing Institute of Collaborative Innovation (BICI), Ph.D. supervisor at the College of Engineering, Peking University, and Director of Jingjinji National Center of Technology Innovation and the Research Center for China's Industry-University-Research Integration and Innovation System. Previously Dr. Wang held positions as Chairman of Xiamen PKU Taipu Technology, Vice Dean of the College of Engineering at Peking University, and Vice President of Southern University of Science and Technology.

     

 

Dr. ZHOU Xinjian

Co-President of Beijing Institute of Collaborative Innovation (BICI) 
President of BICI USA

 

Dr. Zhou received his B.S. and Ph.D. in Physics from Peking University and Cornell University, respectively. Before joining BICI, Dr. Zhou has worked in product development and system engineering as Senior/Staff Engineer at ASML, technology scouting and investment as Venture Manager at Technology-To-Business (TTB) center of Siemens, and technology transfer as BD director at Xerox Palo Alto Research Center (PARC). 

 

 

Dr. WANG Junqi

CEO of ChromX Health Ltd.

 

Dr. Wang is one of the global leaders in the field of micro gas chromatography technology. He participated in the founding and commercialization of Targeted Compound Monitoring, LLC and Kindwell Inc in US, and led the Kindwell Inc team to develop the company’S core technologies and products in the role of CTO.

Incubated by BICI, ChromX Health is a high-tech company focused on developing revolutionary and innovative technologies to fully decode the metabolic molecular information in human breath. ChromX Health integrates Micro-Electro-Mechanical Systems (MEMS) and Artificial Intelligence (AI) in the analysis of biomarkers in breathomics for disease screening, diagnosis, and precision medicine. 

    

Ms. LI Li

Investment Director, BASF Venture Capital
 

Ms. Li graduated from Fudan University majoring in Economics. Joining BASF Venture Capital in 2018, she is responsible for venture capital and invested company management in China. Her investment career began in the China M&A consulting department of PwC; she later joined Voith China and established China's M&A and corporate strategy department, focusing on researching opportunities in Asia's rail transit, energy, paper and other manufacturing industries; Ms. Li also served in the venture capital department of Saudi Basic Industries Corporation and promoted the completion of the team’s first venture capital investment in China.

BASF is an important foreign investment enterprise in China's chemical industry. It has invested more than 6 billion euros in Greater China to date (more than 9 billion euros jointly invested with partners). 

 

 

Enquiries

Dr. Daiying XU

Email    xudaiying@ust.hk

Tel        (852) 23588957

 

(Last Updated on 30 October 2023)